Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema
Operational updates
2021
Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome
Clinical trials
Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer
Operational updates
Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain
Operational updates
Pharming Group to present at Jefferies Virtual Healthcare Conference
Conference attendance
Pharming Reports on Annual General Meeting of Shareholders
Financial updates
Pharming celebrates the 10th annual “hae day :-)”
Other updatesPharming Group N.V. supports the 10th annual “hae-day :-)”, the global awareness day for hereditary angioedema (HAE), a rare life-threatening condition.
Pharming Group reports financial results for the first quarter of 2021
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2021.
Pharming announces enrolment of first patient in multicenter Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
Clinical trialsPharming Group N.V. announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) for the prevention of acute kidney injury after non-ST elevation myocardial infarction at the University Hospital Basel, Switzerland.
Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
Financial updatesPharming Group announces the filing of its Annual Report on Form 20-F for the year ended 31 December 2020 with the U.S. Securities and Exchange Commission (SEC)